chevron_leftBack
As of 13 June 2026, Grace Therapeutics, Inc. has a market cap of $32.5M USD, ranking #33700 globally and #4742 in the United States.
It ranks #3046 in the Healthcare sector, and #1041 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$32.5MUSD
Enterprise Value
$13.51MUSD
EBITDA (TTM)
-$11.24MUSD
Net Income (TTM)
-$5.98MUSD
PB Ratio
0.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Prashant Kohli
open_in_new
Employees
6
Founded
2002
Website
gracetx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | -51% | -55% | -40% | -34% | -16% |
News
Loading...
GRCE Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GRCE
Grace Therapeutics Inc Ordinary Shares
ISIN: US00439U1043
Shares Out.:
Shares Outstanding:
15.474M1
Shares Float:
11.249M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.10 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
2M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
2M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
1M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
843K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
460K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
362K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
989K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
889K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
845K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
559K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
339K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
334K%
80.96B GBP
|
14.6
|
chevron_leftBack